What is the Orange Book?
The “Orange Book” is the FDA’s publication called the Approved Drug Products with Therapeutic Equivalence Evaluations. It lists prescription drugs approved by the U.S. Food and Drug Administration (FDA) and includes information about each product, such as active ingredients, dosage forms, route of administration, and approvals.
It also shows whether FDA considers the drug therapeutically equivalent to other listed versions. This therapeutic equivalence information is what people usually mean when they talk about “Orange Book listings” for generics and brand-drug comparisons.
How is the Orange Book used (especially for generic drugs)?
When a company applies to market a generic version of a drug, it often relies on the Orange Book to confirm the reference (brand) product and to identify therapeutic equivalence relationships.
The Orange Book also includes patent and exclusivity information for some listed products, which can affect whether a generic manufacturer can launch “at risk” or must wait for certain dates to pass.
What kinds of information does it contain?
Orange Book entries commonly include:
- The approved drug product details (active ingredient, strength, dosage form, etc.)
- FDA therapeutic equivalence ratings (to indicate which products are considered equivalent)
- For eligible products, listed patents and exclusivity details tied to FDA-approved marketing
Orange Book vs. other FDA resources
People sometimes confuse the Orange Book with:
- Drug Label (package insert/labeling): the official prescribing information, usually available from FDA or the National Library of Medicine.
- NDC directory: a listing of drug product identifiers (not the therapeutic equivalence/patent-exclusivity focus of the Orange Book).
- Drug development databases: these track trials and approvals but aren’t the same as therapeutic equivalence and patent/exclusivity listings.
Where can I find it?
You can access the Orange Book through FDA’s website. If you’re researching a specific brand/generic dispute, timelines, or patent/exclusivity questions, DrugPatentWatch.com is another place people track these issues alongside FDA listings: https://www.drugpatentwatch.com/
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations)
- https://www.drugpatentwatch.com/